ABSTRACT
Guillain-Barré syndrome (GBS) is the most prevalent cause of acquired paralytic neuropathy in children, however, ataxia as the initial presenting sign in children is very rare. Antiganglioside antibodies are presumed to have an important role in the pathophysiology and some phenotypic correlations have been reported. Anti-GM2 antibody, unlike other antibodies, is far less detected in GBS. Here, we report a 7.5-year-old female, initially presenting with ataxia, an atypical presenting symptom in a child, is promptly diagnosed and treated successfully as GBS. Atypical history of urinary infection in our patient is an interesting aspect. The presence of isolated anti-GM2 IgM antibody and ataxia in a pediatric patient is rare. In this case report, we aim to describe an atypical initial presentation, with positive anti-GM2 antibodies, as well as review literature on isolated anti-GM2 positive pediatric GBS patients.
Subject(s)
Ataxia/etiology , G(M2) Ganglioside/immunology , Guillain-Barre Syndrome/complications , Guillain-Barre Syndrome/immunology , Autoantibodies , Child , Female , HumansABSTRACT
BACKGROUND: Antibodies against ganglioside complexes (GSCs) are associated with various clinical features and subtypes of Guillain-Barré syndrome (GBS). METHODS: One-hundred patients were evaluated for antibodies to GSCs formed by combination of GM1, GM2, GD1a, GD1b, GT1b, and GQ1b using manual enzyme linked immuno-sorbent assay (ELISA). RESULTS: Twenty-six patients were GSC antibody-positive, most frequent being against GM1-containing GSC (76.9%). Gender distribution, mean age, symptom-duration, antecedent events, electrophysiological subtypes, requirement for mechanical ventilation, and median duration of hospital stay were comparable between the GSC antibody-positive and negative groups. There was no association between specific GSC antibody and electrophysiological subtypes or clinical variants. After controlling for false discovery rate (FDR) using the Benjamini-Hochberg method, the number of subjects who improved in overall disability sum score, modified Erasmus GBS outcome score, and neuropathy symptom score at discharge was significantly higher in the GSC antibody-positive group. Improvements in Medical Research Council sum scores and Hughes Disability Scale during the hospital stay between the GSC antibody-positive and negative groups were not significantly different after controlling for FDR. CONCLUSIONS: The GSC antibody-positive group had better outcome at hospital discharge in some of the disability scores. Pathophysiological pathways among patients without GSC antibodies may be different and this requires further evaluation.
Subject(s)
Autoantibodies/immunology , Gangliosides/immunology , Guillain-Barre Syndrome/immunology , Adolescent , Adult , Case-Control Studies , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Female , G(M1) Ganglioside/immunology , G(M2) Ganglioside/immunology , Guillain-Barre Syndrome/physiopathology , Guillain-Barre Syndrome/therapy , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , India , Male , Middle Aged , Plasmapheresis , Respiration, Artificial , Time Factors , Treatment Outcome , Young AdultSubject(s)
Cytomegalovirus Infections/complications , G(M2) Ganglioside/immunology , Guillain-Barre Syndrome/diagnosis , Immunoglobulin M/blood , Adolescent , Biomarkers/blood , Cytomegalovirus Infections/immunology , Female , Guillain-Barre Syndrome/immunology , Guillain-Barre Syndrome/virology , Humans , Severity of Illness IndexSubject(s)
Autoantibodies/immunology , Encephalomyelitis, Acute Disseminated/immunology , G(M2) Ganglioside/immunology , Pneumonia, Mycoplasma/immunology , Brain/diagnostic imaging , Encephalomyelitis, Acute Disseminated/diagnostic imaging , Encephalomyelitis, Acute Disseminated/drug therapy , Female , Glucocorticoids/therapeutic use , Humans , Immunoglobulin M , Magnetic Resonance Imaging , Spinal Cord/diagnostic imaging , Young AdultABSTRACT
BACKGROUND: Multifocal motor neuropathy (MMN) is an acquired immune-mediated form of neuropathy characterized by upper and asymmetric limb weakness without sensory loss. The mean age of onset is 40â¯years (range, 20-70â¯years), and childhood-onset MMN is extremely rare. In the present report, we discuss a case of childhood-onset MMN in a patient who tested positive for anti-GM2 and anti-GalNac-GD1a immunoglobulin M (IgM) antibodies. CASE REPORT: A 12-year-old girl presented with progressive weakness of the upper extremities without sensory loss. Electrophysiological assessments revealed definite conduction blocks in the left median and bilateral radial nerves. She was diagnosed with MMN in accordance with the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria. Serological studies revealed that she tested positive for IgM antibodies to GM2 and GalNac-GD1a. Partial improvements in both muscle weakness and electrophysiological assessments were achieved after 8â¯months of high-dose intravenous immunoglobulin (IVIg) treatment. CONCLUSION: Although childhood-onset MMN is rare, most patients respond to IVIg treatment. This is the first case of childhood-onset MMN in a patient who tested positive for anti-GM2 and anti-GalNac-GD1a IgM antibodies. Although half of the adult patients with MMN test positive for anti-GM1 IgM antibodies, they were not detected in our patient. Comprehensive testing for serum anti-glycolipid antibodies in addition to GM1 may aid in the diagnosis of childhood-onset MMN.
Subject(s)
Autoantibodies/immunology , Immunoglobulin M/immunology , Polyradiculoneuropathy/immunology , Autoantigens/immunology , Child , Female , G(M2) Ganglioside/immunology , Gangliosides/immunology , Humans , Immunoglobulins, Intravenous/therapeutic use , Polyradiculoneuropathy/drug therapyABSTRACT
Bombyx mori cypovirus (BmCPV) enters permissive cells via clathrin-mediated endocytosis pathway. However, the distinct entry mechanism for BmCPV is still ambiguous. The aim of this study is to investigate the role of gangliosides and cholesterol in BmCPV cell entry. The number of BmCPV virions attached to the cell surface and the expression level of BmCPV vp1 gene was significantly decreased by digestion of terminal sialic acids in gangliosides with neuraminidase (NA). Preincubation of different concentration of ganglioside GM1, GM2 or GM3 with BmCPV prior to infection, the reduction of BmCPV infectivity was found by GM2-treated in a dose-depend manner. BmCPV virions were found to colocalize with GM2 in the cell surface. The infectivity of BmCPV was reduced by anti-GM2 antibody treatment cells. Moreover, BmCPV infection was impaired by depletion of membrane cholesterol with MßCD, but the inhibitory effect of MßCD was restored by supplementing with cholesterol. The number of viral particles attached on the BmN cells was significantly decreased by pretreated with MßCD, and BmCPV infection was inhibited by silencing the expression of 3-hydroxy-3-methylglutaryl-CoA reductase gene (Hmg-r) in cholesterol biosynthesis pathway. These results indicate that ganglioside GM2 and cholesterol in membrane lipid rafts are essential for BmCPV attachment to cell surface for its cell entry.
Subject(s)
Bombyx/immunology , Bombyx/virology , Cholesterol/immunology , G(M2) Ganglioside/immunology , Reoviridae/pathogenicity , Virus Internalization , Agriculture , Animals , Arthropod Proteins/genetics , Arthropod Proteins/immunology , Biosynthetic Pathways/genetics , Biosynthetic Pathways/immunology , Capsid Proteins/immunology , Cell Line , Cell Membrane/drug effects , Cell Membrane/immunology , Cholesterol/biosynthesis , Endocytosis/drug effects , Endocytosis/immunology , Host-Pathogen Interactions/immunology , Hydroxymethylglutaryl CoA Reductases/genetics , Hydroxymethylglutaryl CoA Reductases/metabolism , Virion/immunology , Virus Replication/immunology , beta-Cyclodextrins/pharmacologyABSTRACT
A 28-year-old man noticed sensory disturbance in the distal parts of his four extremities and muscle weakness of his hands two weeks after cytomegalovirus (CMV) infection. He had splenomegaly, impairment of hepatic function and peripheral neuropathy with decreased tendon reflexes. Protein-cell dissociation was observed in the cerebrospinal fluid, and the nerve conduction study (NCS) showed the changes due to demyelination. Intravenous immunoglobulin therapy was performed for 5 days after the diagnosis of Guillain-Barré syndrome. He did not show any severe symptoms such as bulbar palsy and was discharged on day 16. Anti-GM2 and anti-GalNAc-GD1a IgM antibodies were detected and acute inflammatory demyelinating polyneuropathy following the CMV infection was confirmed. NCS showed the abnormal changes were normalized after 4 months. The levels of antibodies against moesin, which is a protein existing in trace amounts in node of Ranvier, were increased. However, the antibodies were not detected 4 months after therapy. These changes were well correlated to his clinical course.
Subject(s)
Autoantibodies/blood , Cytomegalovirus Infections/complications , Guillain-Barre Syndrome/diagnosis , Guillain-Barre Syndrome/etiology , Microfilament Proteins/immunology , Adult , Biomarkers/blood , G(M2) Ganglioside/immunology , Guillain-Barre Syndrome/immunology , Guillain-Barre Syndrome/therapy , Humans , Immunoglobulin M/blood , Immunoglobulins, Intravenous/administration & dosage , Male , Neural Conduction , Treatment OutcomeABSTRACT
An efficient method was developed for the synthesis of a GM2 derivative suitable for the conjugation with various biomolecules. This GM2 derivative was covalently linked to keyhole limpet hemocyanin (KLH) and monophosphoryl lipid A (MPLA) to form novel therapeutic cancer vaccines. Immunological evaluations of the resultant conjugates in mice revealed that they elicited robust GM2-specific overall and IgG antibody responses. Moreover, the GM2-MPLA conjugate was disclosed to elicit strong immune responses without the use of an adjuvant, proving its self-adjuvant property. The antisera of both conjugates showed strong binding and mediated similarly effective complement-dependent cytotoxicity to GM2-expressing cancer cell line MCF-7. Based on these results, it was concluded that both GM2-MPLA and GM2-KLH are promising candidates as therapeutic cancer vaccines, whereas fully synthetic GM2-MPLA, which has homogeneous and well-defined structure and self-adjuvant property, deserves more attention and studies.
Subject(s)
Adjuvants, Immunologic , Cancer Vaccines/immunology , G(M2) Ganglioside/immunology , Lipid A/analogs & derivatives , Vaccines, Synthetic/immunology , Animals , Antibody-Dependent Cell Cytotoxicity/immunology , Cancer Vaccines/chemistry , Complement System Proteins/immunology , Disease Models, Animal , Female , G(M2) Ganglioside/chemistry , Lipid A/chemistry , Lipid A/immunology , Mice , Molecular Structure , Neoplasms/immunology , Neoplasms/pathology , Neoplasms/therapy , Vaccines, Synthetic/chemistry , Xenograft Model Antitumor AssaysABSTRACT
Tumor-associated gangliosides have been investigated for their potential as antigenic targets for more than 35 years, culminating in the recent Food and Drug Administration approval of dinutuximab (Unituxin), an IgG antibody targeted against GD2, for the treatment of neuroblastoma in children. This review is focused on discoveries and development of therapeutic approaches involving human IgM antibodies directed against gangliosides, which occurred over the past 40 years at University of California-Los Angeles and the John Wayne Cancer Institute, where Dr. Donald Morton led the surgical oncology department until his death.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antigens, Neoplasm/immunology , Gangliosides/immunology , Immunoglobulin M/therapeutic use , Neoplasms/immunology , Neoplasms/therapy , Antibodies, Monoclonal/immunology , Antigenic Variation , Cancer Vaccines/immunology , G(M2) Ganglioside/immunology , Humans , Immunization, Passive , Immunoglobulin M/immunology , Immunotherapy , Molecular Targeted Therapy , Neoplasms/diagnosisABSTRACT
Multifocal motor neuropathy is a rare immune-mediated neuropathy characterized by progressive asymmetric weakness and atrophy without sensory abnormalities. Although disease onset is usually in adulthood, a few childhood-onset cases have been reported. Here, we report the case of an 8-year-old boy with multifocal motor neuropathy who presented with a slowly progressive left and distal upper limb weakness without sensory loss. The initial high-dose intravenous immunoglobulin treatment significantly improved left upper limb muscle weakness. Continued monthly intravenous immunoglobulin treatment gradually improved muscle strength for several months initially. While the muscle strength decreased slightly after 8 months of therapy, it was better than that before intravenous immunoglobulin treatment. One year and eight months after the initiation of treatment, serum testing for IgM antibodies to gangliosides, GM1 and GM2, was negative. This is the first pediatric report of the serum IgM autoantibodies positive to GM1 and GM2. The clinical course is similar to that of partial intravenous immunoglobulin responders among patients with adulthood-onset multifocal motor neuropathy. Since the symptoms plateaued after the initial intravenous immunoglobulin therapy, prognosis appears to be determined by the patient's initial response to intravenous immunoglobulin treatment.
Subject(s)
G(M1) Ganglioside/immunology , G(M2) Ganglioside/immunology , Immunoglobulin M/blood , Neurodegenerative Diseases/immunology , Neuromuscular Diseases/immunology , Child , Diagnosis, Differential , G(M1) Ganglioside/blood , G(M2) Ganglioside/blood , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Male , Neurodegenerative Diseases/blood , Neurodegenerative Diseases/diagnosis , Neurodegenerative Diseases/drug therapy , Neuromuscular Diseases/blood , Neuromuscular Diseases/diagnosis , Neuromuscular Diseases/drug therapyABSTRACT
Christianson syndrome (CS) is an X-linked neurodevelopmental and neurological disorder characterized in males by core symptoms that include non-verbal status, intellectual disability, epilepsy, truncal ataxia, postnatal microcephaly and hyperkinesis. CS is caused by mutations in the SLC9A6 gene, which encodes a multipass transmembrane sodium (potassium)-hydrogen exchanger 6 (NHE6) protein, functional in early recycling endosomes. The extent and variability of the CS phenotype in female heterozygotes, who presumably express the wild-type and mutant SLC9A6 alleles mosaically as a result of X-chromosome inactivation (XCI), have not yet been systematically characterized. Slc9a6 knockout mice (Slc9a6 KO) were generated by insertion of the bacterial lacZ/ß-galactosidase (ß-Gal) reporter into exon 6 of the X-linked gene. Mutant Slc9a6 KO male mice have been shown to develop late endosomal/lysosomal dysfunction associated with glycolipid accumulation in selected neuronal populations and patterned degeneration of Purkinje cells (PCs). In heterozygous female Slc9a6 KO mice, ß-Gal serves as a transcriptional/XCI reporter and thus facilitates testing of effects of mosaic expression of the mutant allele on penetrance of the abnormal phenotype. Using ß-Gal, we demonstrated mosaic expression of the mutant Slc9a6 allele and mosaically distributed lysosomal glycolipid accumulation and PC pathology in the brains of heterozygous Slc9a6 KO female mice. At the behavioral level, we showed that heterozygous female mice suffer from visuospatial memory and motor coordination deficits similar to but less severe than those observed in X-chromosome hemizygous mutant males. Our studies in heterozygous Slc9a6 KO female mice provide important clues for understanding the likely phenotypic range of Christianson syndrome among females heterozygous for SLC9A6 mutations and might improve diagnostic practice and genetic counseling by helping to characterize this presumably underappreciated patient/carrier group.
Subject(s)
Ataxia/genetics , Epilepsy/genetics , Genetic Diseases, X-Linked/genetics , Intellectual Disability/genetics , Microcephaly/genetics , Mosaicism , Ocular Motility Disorders/genetics , Sodium-Hydrogen Exchangers/genetics , Alleles , Animals , Behavior, Animal , Cognition Disorders/genetics , Disease Models, Animal , Female , G(M2) Ganglioside/immunology , Genotype , Heterozygote , Male , Mice , Mice, Knockout , Mutation , Phenotype , Purkinje Cells/cytology , Sodium-Hydrogen Exchangers/physiologyABSTRACT
BACKGROUND: Guillain-Barré syndrome is the most frequent cause of flaccid paresis in Western countries. Moreover, CMV infection is the most common antecedent viral infection in adult patients and the presence of specific IGM antiganglioside antibodies is often identified. Instead, Guillain-Barré syndrome following CMV infections is rarely reported in childhood and often presents severe symptoms at onset and longer recovery times. MATERIAL AND METHODS: One year of clinical, electrophysiological and serological follow-up of a 9-year old child with axonal sensory-motor Guillain-Barré syndrome following CMV infection is reported. Moreover, the literature data on paediatric sensory-motor axonal GBS and GBS secondary to CMV infection and antiganglioside antibodies are reviewed. RESULTS: Our patient presented with paraesthesias and a pattern of weakness showing proximal predominance and affecting the upper limbs more than the lower limbs. At nadir, unilateral facial palsy was also present and he was unable to walk. Electroneurography showed motor-sensory axonal damage. Both anti-CMV and anti-GM2 IgM were positive. After early treatment with IVIG and IV methylprednisolone the patient recovered deambulation. Six months later, his neurological examination was normal and electroneurography showed normal data. CONCLUSION: The sensory-motor axonal form of Guillain-Barré syndrome following CMV infection may present a good prognosis and a prompt full recovery also in children, if adequate treatment is started in time.
Subject(s)
Cytomegalovirus Infections/complications , Guillain-Barre Syndrome/virology , Anti-Inflammatory Agents/therapeutic use , Antibodies, Viral/blood , Autoantibodies/blood , Autoantigens/blood , Child , G(M2) Ganglioside/immunology , Guillain-Barre Syndrome/drug therapy , Guillain-Barre Syndrome/immunology , Humans , Immunoglobulins, Intravenous/therapeutic use , Male , Methylprednisolone/therapeutic useABSTRACT
Malignant pleural mesothelioma (MPM) is a rare and highly aggressive neoplasm that arises from the pleural, pericardial, or peritoneal lining. Although surgery, chemotherapy, radiotherapy, and combinations of these therapies are used to treat MPM, the median survival of such patients is dismal. Therefore, there is a compelling need to develop novel therapeutics with different modes of action. Ganglioside GM2 is a glycolipid that has been shown to be overexpressed in various types of cancer. However, there are no published reports regarding the use of GM2 as a potential therapeutic target in cases of MPM. In this study, we evaluated the efficacy of the anti-GM2 antibody BIW-8962 as an anti-MPM therapeutic using in vitro and in vivo assays. Consequently, the GM2 expression in the MPM cell lines was confirmed using flow cytometry. In addition, eight of 11 cell lines were GM2-positive (73%), although the GM2 expression was variable. BIW-8962 showed a significant antibody-dependent cellular cytotoxicity activity against the GM2-expressing MPM cell line MSTO-211H, the effect of which depended on the antibody concentration and effector/target ratio. In an in vivo orthotropic mouse model using MSTO-211H cells, BIW-8962 significantly decreased the incidence and size of tumors. Additionally, the GM2 expression was confirmed in the MPM clinical specimens. Fifty-eight percent of the MPM tumors were positive for GM2, with individual variation in the intensity and frequency of staining. These data suggest that anti-GM2 antibodies may become a therapeutic option for MPM patients.
Subject(s)
Antibodies, Monoclonal, Humanized/pharmacology , Antineoplastic Agents/pharmacology , G(M2) Ganglioside/immunology , Lung Neoplasms/drug therapy , Mesothelioma/drug therapy , Pleural Neoplasms/drug therapy , Aged , Aged, 80 and over , Animals , Antibodies, Monoclonal, Humanized/therapeutic use , Antibody-Dependent Cell Cytotoxicity , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , Female , G(M2) Ganglioside/metabolism , Humans , Male , Mesothelioma, Malignant , Mice, SCID , Middle Aged , Protein Engineering , Xenograft Model Antitumor AssaysABSTRACT
We evaluated Eastern Cooperative Group phase II and III trials E2696 and E1694 to assess the incidence and prognostic significance of autoimmunity induced by adjuvant high-dose interferon-α2b (HDI). In E2696, patients with resectable high-risk melanoma were randomized to receive vaccination with GM2-KLH/QS-1 (GMK) plus concurrent HDI, GMK plus sequential HDI, or GMK alone. E1694 randomized patients to either HDI or GMK. Sera from 103 patients in E2696 and 691 patients in E1694 banked at baseline and up to three subsequent time points were tested by ELISA for the development of five autoantibodies. In E2696, autoantibodies were induced in 16 patients (23.2%; n=69) receiving HDI and GMK and two patients (5.9%; n=34) receiving GMK alone (P=0.031). Of 691 patients in E1694, 67 (19.1%) who received HDI (n=350) developed autoantibodies, but only 16 patients (4.7%) developed autoantibodies in the vaccine group (n=341; P<0.001). Almost all induced autoantibodies were detected at ≥12 weeks after the initiation of therapy. A 1-year landmark analysis among resected stage III patients treated with HDI in E1694 showed a trend toward a survival advantage associated with HDI-induced autoimmunity (hazard ratio=0.80; 95% confidence interval: 0.50-1.98; P=0.33). Therefore, adjuvant HDI therapy is associated with the induction of autoimmunity that should be further investigated prospectively as a surrogate marker of adjuvant therapeutic benefit. This potential biomarker develops over the course of up to 1 year, and cannot be used to alter the course of therapy. Studies of the genetic determinants of this response may better discriminate patients more likely to benefit from HDI immunomodulatory therapy.
Subject(s)
Autoantibodies/blood , Cancer Vaccines/therapeutic use , Interferon-alpha/therapeutic use , Melanoma/blood , Melanoma/immunology , Skin Neoplasms/blood , Skin Neoplasms/immunology , Autoantibodies/biosynthesis , Autoimmunity , Chemotherapy, Adjuvant , Disease-Free Survival , Enzyme-Linked Immunosorbent Assay , G(M2) Ganglioside/immunology , G(M2) Ganglioside/therapeutic use , Hemocyanins/immunology , Hemocyanins/therapeutic use , Humans , Melanoma/drug therapy , Prognosis , Skin Neoplasms/drug therapyABSTRACT
We herein present the case of a 38-year-old woman with left-sided oculomotor paralysis with ocular pain that developed after a respiratory infection. Her serum was positive for IgM against GM2 and GalNAc-GD1a gangliosides and cytomegalovirus. Thin-slice magnetic resonance imaging revealed enhanced abnormal tissue located primarily in the superolateral part of the left-sided cavernous sinus, which corticosteroids subsequently obscured with immediate resolution of the patient's ocular symptoms. These clinical features were consistent with those of Tolosa-Hunt syndrome (THS). Our findings in the present patient suggest that cytomegalovirus may provoke granuloma formation in the cavernous sinus, as reported in other various organs, thereby leading to the development of THS.
Subject(s)
Cytomegalovirus Infections/complications , Cytomegalovirus/pathogenicity , Respiratory Tract Infections/complications , Tolosa-Hunt Syndrome/etiology , Adult , Antibodies, Viral/blood , Autoantibodies/blood , Autoantibodies/immunology , Cavernous Sinus/virology , Cytomegalovirus/immunology , Cytomegalovirus Infections/immunology , Diplopia/etiology , Female , G(M1) Ganglioside/analogs & derivatives , G(M1) Ganglioside/immunology , G(M2) Ganglioside/immunology , Granuloma/etiology , Granuloma/virology , Humans , Imaging, Three-Dimensional , Immunocompetence , Immunoglobulin M/blood , Macrophages/immunology , Macrophages/pathology , Magnetic Resonance Imaging , Prednisolone/therapeutic use , Respiratory Tract Infections/immunology , Respiratory Tract Infections/virology , Tolosa-Hunt Syndrome/drug therapy , Tolosa-Hunt Syndrome/immunology , Tolosa-Hunt Syndrome/pathology , Tolosa-Hunt Syndrome/virologyABSTRACT
Acute canine polyradiculoneuritis (ACP) is considered to be the canine equivalent of the human peripheral nerve disorder Guillain-Barré syndrome (GBS); an aetiological relationship, however, remains to be demonstrated. In GBS, anti-glycolipid antibodies (Abs) are considered as important disease mediators. To address the possibility of common Ab biomarkers, the sera of 25 ACP dogs, 19 non-neurological, and 15 epileptic control dogs were screened for IgG Abs to 10 glycolipids and their 1 : 1 heteromeric complexes using combinatorial glycoarrays. Anti-GM2 ganglioside Abs were detected in 14/25 ACP dogs, and anti-GA1 Abs in one further dog. All controls except for one were negative for anti-glycolipid Abs. In this cohort of cases and controls, the glycoarray screen reached a diagnostic sensitivity of 60% and a specificity of 97%; a lower sensitivity (32%) was reported using a conventional glycolipid ELISA. To address the possible pathogenic role for anti-GM2 Abs in ACP, we identified GM2 in canine sciatic nerve by both mass spectrometry and thin layer chromatography overlay. In immunohistological studies, GM2 was localized predominantly to the abaxonal Schwann cell membrane. The presence of anti-GM2 Abs in ACP suggests that it may share a similar pathophysiology with GBS, for which it could thus be considered a naturally occurring animal model.
Subject(s)
Biomarkers/blood , G(M2) Ganglioside/immunology , Immunoglobulin G/blood , Polyradiculoneuropathy/blood , Polyradiculoneuropathy/veterinary , Acute Disease , Animals , Chromatography, Thin Layer , Diagnostic Imaging , Dogs , Electric Stimulation , Electromyography , Enzyme-Linked Immunosorbent Assay , Evoked Potentials, Motor/physiology , Female , Magnetic Resonance Imaging , Male , Neurologic Examination , Polyradiculoneuropathy/diagnosis , Polyradiculoneuropathy/physiopathology , Sciatic Nerve/pathology , Spinal Cord/pathology , Statistics as TopicABSTRACT
Gangliosides are glycosphingolipids highly enriched in neural plasma membranes, where they mediate a diverse range of functions and can act as targets for auto-antibodies present in human immune-mediated neuropathy sera. The ensuing autoimmune injury results in axonal and motor nerve terminal (mNT) degeneration. Both aging and ganglioside-deficiency have been linked to impaired axonal regeneration. To assess the effects of age and ganglioside expression on mNT regeneration in an autoimmune injury paradigm, anti-ganglioside antibodies and complement were applied to young adult and aged mice wildtype (WT) mice, mice deficient in either b- and c-series (GD3sKO) or mice deficient in all complex gangliosides (GM2sKO). The extent of mNT injury and regeneration was assessed immediately or after 5 days, respectively. Depending on ganglioside expression and antibody-specificity, either a selective mNT injury or a combined injury of mNTs and neuromuscular glial cells was elicited. Immediately after induction of the injury, between 1.5% and 11.8% of neuromuscular junctions (NMJs) in the young adult groups exhibited healthy mNTs. Five days later, most NMJs, regardless of age and strain, had recovered their mNTs. No significant differences could be observed between young and aged WT and GM2sKO mice; aged GD3sKO showed a mildly impaired rate of mNT regeneration when compared with their younger counterparts. Comparable rates were observed between all strains in the young and the aged mice. In summary, the rate of mNT regeneration following anti-ganglioside antibody and complement-mediated injury does not differ majorly between young adult and aged mice irrespective of the expression of particular gangliosides.
Subject(s)
Autoantibodies/immunology , Autoimmune Diseases of the Nervous System/immunology , G(M2) Ganglioside/metabolism , Gangliosides/metabolism , Nerve Regeneration/immunology , Neuromuscular Junction/immunology , Age Factors , Animals , Complement System Proteins/immunology , G(M2) Ganglioside/immunology , Gangliosides/immunology , Mice , Mice, Knockout , N-Acetylgalactosaminyltransferases/genetics , N-Acetylgalactosaminyltransferases/metabolism , Neuromuscular Junction/physiopathology , Schwann Cells/metabolism , Schwann Cells/physiology , Sialyltransferases/genetics , Sialyltransferases/metabolismABSTRACT
Lymphoproliferative disorders are often associated with autoimmune processes preceding or following the occurrence of a lymphoma. Here, we describe a patient with a history of recurrent diffuse large B-cell non-Hodgkin's lymphoma who suffered from an acute inflammatory neuropathy with specific monoclonal anti-GM2 IgM antibodies and associated IgM-κ paraprotein. It was possible in this case to prove that both, anti-GM2 IgM antibodies and IgM-κ paraprotein, share the same binding characteristic. In addition, the patient possibly suffered from an immune thrombocytopenia and an early-stage bullous pemphigoid with anti-BP-230 IgG antibodies. Intravenous immunoglobulin and plasmapheresis alleviated the acute neuropathy and thrombocytopenia, while the bullous pemphigoid has been aggravated. In summary, the simultaneous occurrence of multiple autoimmune processes was a sign of a dysfunctional immune system preceding the relapse of a B-cell non-Hodgkin's lymphoma.
Subject(s)
Cranial Nerve Diseases/immunology , G(M2) Ganglioside/immunology , Immunoglobulin M/blood , Lymphoma, Large B-Cell, Diffuse/complications , Paraproteins/metabolism , Polyradiculoneuropathy/immunology , Aged , Cranial Nerve Diseases/complications , Cranial Nerve Diseases/therapy , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Lymphoma, Large B-Cell, Diffuse/drug therapy , Male , Pemphigoid, Bullous/complications , Plasmapheresis , Polyradiculoneuropathy/complications , Polyradiculoneuropathy/therapy , Recurrence , Thrombocytopenia/complicationsABSTRACT
A 36-year-old man was admitted to our hospital because of urinary retention and muscle weakness affecting all 4 limbs after receiving a H1N1 09 influenza vaccination. Magnetic resonance imaging demonstrated multiple lesions in his brain and spinal cord. Furthermore, nerve conduction study showed acute sensorimotor neuropathy, and anti-GM2 antibodies were detected in his serum. Based on the temporal association and exclusion of alternative etiologies, we made a diagnosis of acute disseminated encephalomyelitis (ADEM) and Guillain-Barré syndrome (GBS). To our knowledge, this is the first case of co-morbid ADEM and GBS after influenza vaccination with positive anti-ganglioside antibodies.